<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3580">
  <stage>Registered</stage>
  <submitdate>5/06/2012</submitdate>
  <approvaldate>5/06/2012</approvaldate>
  <nctid>NCT01627691</nctid>
  <trial_identification>
    <studytitle>REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System</studytitle>
    <scientifictitle>REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Evaluation of Safety and Performance</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TP3687</secondaryid>
    <secondaryid>TP3687</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Transcatheter Aortic Valve Replacement</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Lotus Valve System

Experimental: Lotus Valve System - Patients enrolled will receive the Lotus Valve.


Treatment: devices: Lotus Valve System
bioprosthetic bovine pericardial aortic valve
delivery system

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Device Performance Endpoint: Mean aortic valve pressure gradient at 30 days post implant procedure - Mean aortic valve pressure gradient at 30 days post implant procedure as measured by echocardiography and assessed by an independent core laboratory.</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint: All-cause mortality at 30 days post implant procedure - All-cause mortality at 30 days post implant procedure</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject is =70 years of age

          -  Subject has documented calcific native aortic valve stenosis

          -  Subject has a documented aortic annulus size between =19 and =27 mm based on
             pre-procedure diagnostic imaging

          -  Symptomatic aortic valve stenosis with NYHA Functional Class = II

          -  Subject is considered high risk for surgical valve replacement

          -  Heart team assessment that the subject is likely to benefit from valve replacement.

          -  Subject (or legal representative) understands the study requirements and the treatment
             procedures, and provides written informed consent.

          -  Subject, family member, and/or legal representative agree(s) and subject is capable of
             returning to the study hospital for all required scheduled follow up visits.</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has a congenital unicuspid or bicuspid aortic valve.

          -  Subject with an acute myocardial infarction within 30 days of the index procedure

          -  Subject has had a cerebrovascular accident or transient ischemic attack within the
             past 6 months, or has any permanent neurologic defect prior to study enrollment.

          -  Subject is on dialysis or has serum creatinine level &gt;3.0 mg/dL or 265 µmol/L.

          -  Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic
             ring in any position.

          -  subject cannot have more than moderate mitral, aortic or tricuspid regurgitation

          -  Subject has a need for emergency surgery for any reason.

          -  Subject has a history of endocarditis within 12 months of index procedure or evidence
             of an active systemic infection or sepsis.

          -  Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.

          -  Subject has low Hgb, platelet count or &gt;700,000 cells/mm3, or low white blood cell
             count.

          -  Subject requires chronic anticoagulation therapy and cannot tolerate concomitant
             therapy with either aspirin or clopidogrel/ticlopidine

          -  Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3
             months, other bleeding diathesis or coagulopathy or will refuse transfusions.

          -  Subject has known hypersensitivity to contrast agents that cannot be adequately
             pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin,
             nickel, tantalum, titanium, or polyurethanes.

          -  Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid
             conditions based on the assessment of the investigator at the time of enrollment.

          -  Subject has hypertrophic obstructive cardiomyopathy.

          -  Subject has any therapeutic invasive cardiac procedure within 30 days prior to the
             index procedure (except for pacemaker implantation which is allowed).

          -  Subject has untreated coronary artery disease.

          -  Subject has documented left ventricular ejection fraction &lt;30%.

          -  Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic
             support or mechanical support devices.

          -  Subject has severe peripheral vascular disease or symptomatic carotid or vertebral
             disease.

          -  Narrow Femoral artery lumen precludes the use of either Lotus device size, or severe
             iliofemoral tortuosity or calcification that would prevent safe placement of the
             introducer sheath.

          -  Current problems with substance abuse (e.g., alcohol, etc.).

          -  Subject is participating in another investigational drug or device study that has not
             reached its primary endpoint.

          -  Patient has preexisting untreated conduction system disorder that requires new
             pacemaker implantation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>8/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>250</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>13/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Prince Charles Hospital - Brisbane</hospital>
    <hospital>Monash Medical Center - Melbourne</hospital>
    <hospital>St. Vincent's Hospital - Melbourne</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Siegburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and performance of the Lotus Valve
      System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with severe
      calcific aortic stenosis who are considered high risk for surgical valve replacement.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01627691</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ian Meredith, Professor</name>
      <address>Monash Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>